Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes

BACKGROUND. Previous efforts to preserve β cell function in individuals with type 1 diabetes (T1D) have focused largely on the use of single immunomodulatory agents administered within 100 days of diagnosis. Based on human and preclinical studies, we hypothesized that a combination of low-dose anti-...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Invest
Päätekijät: Haller, Michael J., Gitelman, Stephen E., Gottlieb, Peter A., Michels, Aaron W., Rosenthal, Stephen M., Shuster, Jonathan J., Zou, Baiming, Brusko, Todd M., Hulme, Maigan A., Wasserfall, Clive H., Mathews, Clayton E., Atkinson, Mark A., Schatz, Desmond A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Clinical Investigation 2014
Aiheet:
Clinical Medicine
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4382237/
https://ncbi.nlm.nih.gov/pubmed/25500887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI78492
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia